M&A Deal Summary |
|
|---|---|
| Date | 2024-07-24 |
| Target | JenaValve Technology |
| Sector | Medical Products |
| Buyer(s) | Edwards |
| Sellers(s) |
GIMV
Andera Partners |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1958 |
| Sector | Medical Products |
| Employees | 19,800 |
| Revenue | 6.0B USD (2023) |
Edwards is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. Edwards was founded in 1958 and is based in Irvine, California.
| DEAL STATS | # |
|---|---|
| Overall | 14 of 15 |
| Sector (Medical Products) | 11 of 12 |
| Type (Add-on Acquisition) | 8 of 9 |
| State (California) | 4 of 4 |
| Country (United States) | 10 of 11 |
| Year (2024) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-06-03 |
Critical Care
Irvine, California, United States Critical Care is a provider of advanced patient monitoring with advanced AI algorithms serving millions of patients globally. Critical Care is based in Irvine, California. |
Sell | $4.2B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-08-20 |
Endotronix
Lisle, Illinois, United States Endotronix is a digital health medtech company developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from chronic heart failure. Endotronix was founded in 2007 and is based in Lisle, Illinois. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 1980 |
| PE ASSETS | 2.0B EUR |
| Size | Large |
| Type | Sector Agnostic |
GIMV is a Belgium based public investment company focused on private equity and venture capital investments in tech-based businesses. GIMV's private equity practice operates through its Corporate Investment unit and targets management buyouts, buy-ins, and growth capital financings of companies with annual sales between EUR15 and EUR150 million. For buyout opportunities GIMV generally takes a majority stake in businesses and for growth capital needs, GIMV takes a minority position. GIMV does not invest in publicly held companies or turnaround situations. GIMV's geographic focus is within Belgium, Netherlands, Germany, and France. GIMV also invests in Russia through Eagle Capital Partners, a partnership with KBC Private Equity. GIMV was formed in 1980 and is headquartered in Antwerp with additional offices in The Hague, Frankfurt, Munich, and Paris.
| DEAL STATS | # |
|---|---|
| Overall | 105 of 105 |
| Sector (Medical Products) | 4 of 4 |
| Type (Add-on Acquisition) | 52 of 52 |
| State (California) | 3 of 3 |
| Country (United States) | 5 of 5 |
| Year (2024) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-06-07 |
SMG Sportplatzmaschinenbau
Vohringen, Germany SMG Sportplatzmaschinenbau is developing modern machines for laying synthetic flooring in the sports sector. SMG has also been introducing world firsts for the maintenance of artificial turf or carpets with granulate infill since the 1980s. For almost half a century, SMG has offered a unique range of machines. SMG Sportplatzmaschinenbau was founded in 1975 and is based in Vohringen, Germany. |
Buy | - |
| Category | Private Equity Firm |
|---|---|
| Founded | 2001 |
| PE ASSETS | 3.7B EUR |
| Size | Large |
| Type | Sector Agnostic |
Andera Partners is a private investment firm focused on several strategies. The Firm invests in life science opportunities through its BioDiscovery group. The Firm invests in Western European small to mid-sized companies (€30 to €300 million of revenue) through its Winch Capital group. Andera invests in small to mid-sized French companies (€10 to €100 million of revenue) through its Cabestan Capital team. Andera invests in €5 to €45 million of mezzanine capital to support small to mid-sized French companies. Andera Partners was established in 2001 and is headquartered in Paris.
| DEAL STATS | # |
|---|---|
| Overall | 39 of 39 |
| Sector (Medical Products) | 3 of 3 |
| Type (Add-on Acquisition) | 14 of 14 |
| State (California) | 2 of 2 |
| Country (United States) | 3 of 3 |
| Year (2024) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-03-14 |
Amolyt Pharma
Ecully, France Amolyt Pharma is a clinical-stage biotechnology company, building therapeutic peptides to deliver life-changing treatments to patients suffering from rare endocrine and related diseases. Amolyt Pharma was founded in 2015 and is based in Ecully, France. |
Sell | $1.1B |
